Guillain-Barré Syndrome
Clinical Snapshot
Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyneuropathy and the most frequent cause of subacute neuromuscular weakness in North America.[1] In most cases, the immune response to a preceding infection cross-reacts with peripheral nerve components through molecular mimicry: antibodies raised against infectious antigens — most classically the lipooligosaccharides of Campylobacter jejuni — structurally resemble gangliosides that reside at high density in the axolemma of peripheral nerves, triggering complement activation, macrophage infiltration, and inflammatory edema of the nerve roots and peripheral nerves.[2] The result is an ascending immune-mediated polyneuropathy — weakness beginning in the legs and progressing upward — that can be predominantly demyelinating (acute inflammatory demyelinating polyradiculoneuropathy, AIDP, the most common pattern in North America and Europe) or predominantly axonal (acute motor axonal neuropathy, AMAN, or acute motor sensory axonal neuropathy, AMSAN).[2]
Ascending, not descending — the single most useful pattern-recognition anchor. GBS weakness classically starts distally in the legs and ascends toward the trunk, arms, and cranial nerves last — the mirror image of botulism's toxin-mediated, symmetric descending paralysis that begins with the cranial nerves. Sensory symptoms, reduced or absent deep tendon reflexes, and a genuinely progressive course over hours to a few weeks help confirm GBS rather than a phenocopy — see Assessment & Diagnosis for the full comparison.
GBS is fundamentally an emergency-recognition condition: autonomic dysfunction and respiratory muscle weakness can progress — sometimes rapidly — to require ICU-level monitoring and mechanical ventilation, and this evolving trajectory, more than any single finding at presentation, is why early recognition and close monitoring for respiratory decline is the central safety message of this chapter.[1] Two disease-modifying therapies — intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis) — are equally effective at hastening recovery; corticosteroids, despite being immunosuppressive, are specifically not effective in GBS and are not recommended, a genuine exception to how many other autoimmune neurologic conditions are treated.[3][4]
Recognize the Condition
Epidemiology
The median incidence of GBS is about 1 per 100,000 person-years, with a roughly 20% increase in the average rate for every 10-year increase in age, and higher rates in males.[1] Worldwide estimates run somewhat higher, at 1 to 4 per 100,000 population annually; GBS causes respiratory failure requiring ventilation in about 25% of patients, with associated mortality of 4-15% and persistent disability in about 20%.[3]
Antecedent triggers — infection, and the honest vaccine-safety context
A majority of patients report an antecedent infectious illness, typically respiratory or gastrointestinal, in the 1 to 3 weeks (occasionally longer) before weakness begins.[2] Campylobacter jejuni gastroenteritis is the most classically associated trigger, but cytomegalovirus, hepatitis E virus, and Zika virus, among other pathogens, have each been linked to GBS in case-control studies.[2][1]
GBS can also very rarely follow vaccination, and this deserves honest, proportionate treatment rather than either dismissal or alarm. A large retrospective cohort study published in 2013 found no overall increased risk of GBS after vaccination.[1] At the same time, Canadian vaccine safety surveillance treats GBS as a genuine adverse event of special interest and classifies reported cases by diagnostic certainty using the internationally standardized Brighton Collaboration case definition.[5] During the COVID-19 vaccination program, the Public Health Agency of Canada and Health Canada identified and actively monitored a specific, real safety signal: as of July 2021, Canada had received 85 reports of GBS meeting Brighton diagnostic-certainty criteria following COVID-19 vaccination — 32 after AstraZeneca Vaxzevria/COVISHIELD, 34 after Pfizer-BioNTech Comirnaty, and 19 after Moderna Spikevax — with the AstraZeneca-associated reports (23 after a first dose, onset 6 hours to 25 days later, median age 55) occurring at a rate the report described as higher than would normally be expected in the general population, prompting formal signal monitoring as one of three ongoing safety signals at that time.[5] The clinically useful takeaway for a pharmacist is not to discourage immunization, but to recognize that a genuine, small, product-specific association existed for adenovirus-vector COVID-19 vaccines, and to take any new ascending weakness seriously regardless of a recent vaccination, infection, both, or neither.
Classic presentation
In primary care, patients most commonly present first with acroparesthesias, followed by subacute (developing over less than 4 weeks), symmetric, flaccid weakness with hyporeflexia; weakness usually begins in the lower extremities and ascends.[1] Sensory symptoms are variable — many patients have paresthesias or mild sensory loss, though predominantly motor presentations occur, particularly in the axonal subtypes.[2] As weakness progresses, watch specifically for the two features that define this chapter's central safety message: autonomic dysfunction (labile blood pressure, arrhythmia, ileus, urinary retention) and respiratory muscle weakness, either of which can progress — sometimes over hours — to require ICU-level monitoring and mechanical ventilation; nearly one-third of patients with GBS require mechanical ventilation.[1]
Subtypes and variants
Recognizing which pattern is present
AIDP — acute inflammatory demyelinating polyradiculoneuropathy
The most common subtype in North America and Europe, targeting the myelin sheath; nerve conduction studies show a demyelinating pattern.
AMAN — acute motor axonal neuropathy
A predominantly motor, axonal pattern, more common in parts of Asia and Central/South America, and the pattern most classically linked to preceding Campylobacter jejuni infection.
AMSAN — acute motor sensory axonal neuropathy
An axonal pattern involving both motor and sensory fibres, generally with more severe weakness and slower recovery than AIDP.
Miller Fisher syndrome
The triad of ophthalmoplegia, areflexia, and ataxia, representing roughly 5-25% of the GBS clinical spectrum; typically a milder course, though a subgroup goes on to develop the limb weakness of classic GBS.
Risk Factors
- Antecedent Campylobacter jejuni gastroenteritis — the most classically associated and most extensively studied trigger, and the trigger most strongly linked to the axonal (AMAN) subtype.[2]
- Other antecedent infections, including cytomegalovirus, hepatitis E virus, and Zika virus.[2]
- Recent vaccination, very rarely — see Recognize the Condition for the specific, honestly presented Canadian surveillance data; the great majority of GBS has no vaccine association at all.[1][5]
- Older age — each 10-year increase in age raises the average GBS rate by about 20%.[1]
- Male sex — a modestly higher incidence than in women.[1]
- No preceding trigger is identified in a meaningful minority of patients — a clear antecedent event is not required to consider the diagnosis.
Red Flags & Refer
Any patient with new, progressive, symmetric weakness should be evaluated for GBS urgently — this entire chapter is fundamentally about recognizing that pattern before it progresses to respiratory or autonomic crisis. Refer for same-day/emergency neurologic and, in most cases, hospital-level assessment for:
- Progressive, ascending weakness, particularly with reduced or absent reflexes, developing over hours to a few weeks.[1]
- Any inability to walk 10 metres unaided, or rapid progression over less than 2 weeks — both change the treatment calculus (see Choose Initial Treatment) and warrant admission regardless of respiratory status at that moment.[3]
- Respiratory decline — the single most time-critical deterioration to catch early: new dyspnea or breathlessness lying flat, difficulty swallowing or handling secretions, a weak or breathless-sounding cough, or a declining, serially measured vital capacity. Do not wait for overt respiratory failure — proactive, low-threshold escalation is the standard (see Non-Pharmacologic Management and the Clinical Decision Algorithm).[6][2]
- Autonomic instability: marked blood pressure lability, a new arrhythmia, or significant ileus/urinary retention.[2]
- Bulbar weakness (facial weakness, dysarthria, dysphagia) or ophthalmoplegia, which can herald more diffuse cranial nerve and respiratory involvement, or represent the Miller Fisher variant.[2]
The pharmacist's role here is recognition and immediate escalation — as with any acute neuromuscular emergency — not outpatient reassurance or a "monitor and see" approach.
Assessment & Diagnosis
GBS is primarily a clinical diagnosis
Diagnosis rests on the history and examination pattern described in Recognize the Condition — subacute, ascending, symmetric weakness with hyporeflexia — supported by cerebrospinal fluid (CSF) analysis and nerve conduction studies; it should not wait for either test to be completed before initiating monitoring and, where indicated, treatment.[1]
CSF analysis — collect it, and know what it should (and should not) show
Collect CSF on presentation, both to support the diagnosis and to exclude infectious mimics.[1] The classic finding is albuminocytologic dissociation — an elevated CSF protein with a normal white blood cell count — present in 50-70% of GBS cases in the first week of illness, so a normal early CSF protein does not exclude the diagnosis.[1] Pleocytosis is a red flag against GBS, not a supportive finding, and should prompt evaluation for an infectious mimic such as Lyme disease, HIV, enterovirus, or West Nile virus instead.[1]
Nerve conduction studies and electromyography
Electrodiagnostic testing supports subtyping into a demyelinating pattern (AIDP) or an axonal pattern (AMAN/AMSAN), though testing can be normal early in the illness and should not be used to exclude the diagnosis when the clinical picture is convincing.[2] The distinction matters for counseling: an axonal subtype, or unexcitable nerves on early testing, predicts a longer course to mechanical-ventilation weaning and a slower recovery.[2]
Differentiating GBS from its principal mimics
| Feature | Guillain-Barré syndrome | Botulism | Myasthenia gravis |
|---|---|---|---|
| Pattern of weakness | Symmetric, ascending — starts distally in the legs | Symmetric, descending — starts with the cranial nerves | Fluctuating and fatigable; often ocular/bulbar early, not a true ascending or descending pattern |
| Sensory findings | Often present — paresthesias, variable sensory loss | None | None |
| Reflexes | Reduced or absent | Usually preserved until late | Normal |
| Fever | Usually absent | Absent, unless a complicating infection is present | Absent |
| CSF protein | Often elevated with a normal cell count (albuminocytologic dissociation) | Normal | Normal |
| Antecedent event | Infection in the preceding 1-3 weeks in most cases; rarely vaccination | Contaminated food, a wound, or (in infants) ingested spores | Often none identifiable |
Predicting the need for mechanical ventilation — the EGRIS score
The Erasmus GBS Respiratory Insufficiency Score (EGRIS) combines three variables available at hospital admission — the number of days between the onset of weakness and admission, the presence of facial and/or bulbar weakness, and the total Medical Research Council (MRC) sum score for muscle strength — into a single score used to estimate the probability of needing mechanical ventilation within the first week.[7] It is presented here as a teaching reference to frame clinical urgency, not as a live calculator or a substitute for the serial bedside respiratory monitoring described in Non-Pharmacologic Management.
| EGRIS score | Approximate risk of needing mechanical ventilation within 1 week |
|---|---|
| 0-2 (low) | About 4% |
| 3-4 (intermediate) | About 24% |
| 5 or higher (high) | About 65% |
Treatment Targets
- Halt further immune-mediated nerve injury and hasten recovery with disease-modifying immunotherapy — IVIG or plasma exchange — started as early as possible in an appropriately selected patient.
- Anticipate and prevent respiratory crisis through proactive serial monitoring rather than reactive management after overt failure.
- Recognize and manage autonomic dysfunction safely, including cardiac monitoring and cautious, conservative treatment of blood pressure lability and arrhythmia.
- Prevent venous thromboembolism during the period of immobility.
- Treat neuropathic and nociceptive pain effectively — pain is common, can be severe, and is under-recognized.
- Support the patient and family through a genuinely variable, often prolonged recovery course with realistic counseling and proactive rehabilitation referral.
- Avoid ineffective or harmful therapy — most importantly, corticosteroids and combined or sequential IVIG-plus-plasma-exchange regimens, neither of which adds benefit.
Choose Initial Treatment
IVIG or plasma exchange — equally effective, choose one, do not combine
Non-ambulatory patients (unable to walk 10 metres unaided) started within 4 weeks of the onset of neuropathic symptoms: treat with either IVIG or plasma exchange (PLEX) — both are Level A-supported and equally effective at improving disability after 4 weeks; the choice depends on availability, contraindications, and local expertise rather than any proven superiority of one over the other.[3][1] IVIG is generally easier to administer and carries a more favourable side-effect profile than plasma exchange, which requires specialized apheresis resources and dedicated vascular access.[3]
Ambulatory patients with rapidly progressive weakness started within 2 weeks of onset: IVIG and PLEX have comparable efficacy in patients requiring walking aids if started this early.[3]
Do not combine or sequence the two treatments — sequential treatment with plasma exchange followed by IVIG does not have a greater effect than either treatment given alone (Level A).[3]
IVIG dosing
Total dose 2 g/kg IV, given as 0.4 g/kg once daily for 5 consecutive days.[2] Screen for known IgA deficiency where feasible before the first infusion (see Special Populations), and infuse at the slowest rate consistent with the product monograph, particularly in patients with renal impairment, diabetes, or volume depletion.
Plasma exchange protocol
Typically five exchanges, together removing a total of about 200-250 mL of plasma per kg body weight, performed via a large-bore central catheter over roughly 1-2 weeks.[2] Plasma exchange carries a somewhat higher risk of treatment-related side effects than IVIG and is more difficult to administer, largely reflecting the vascular-access and apheresis-resource requirements rather than any lesser efficacy.[3]
Corticosteroids are NOT effective in GBS — a genuine, important exception
Do not use corticosteroids to treat GBS, alone or added to IVIG — this is Level A evidence against benefit, not a judgment call.[3] A randomized trial of 233 patients found that adding IV methylprednisolone 500 mg daily for 5 days to standard IVIG produced no significant improvement over IVIG alone.[4] This is a genuinely important point of contrast: unlike myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and many other autoimmune neurologic conditions where corticosteroids are foundational first-line immunosuppressive therapy, GBS is a specific, well-documented exception where steroids simply do not work despite the disease being immune-mediated.
Non-Pharmacologic Treatment
- Admit every patient with confirmed or strongly suspected GBS for monitoring, regardless of how mild weakness appears at presentation — the course is genuinely unpredictable early on.[1]
- Serial respiratory monitoring: measure vital capacity (VC), maximal inspiratory pressure (MIP, also called negative inspiratory force/NIF), and maximal expiratory pressure (MEP) every 4-6 hours, more frequently if any parameter is declining or the patient is symptomatic. The "20/30/40 rule" — VC under 20 mL/kg, MIP less negative than 30 cm H2O, or MEP under 40 cm H2O, or a decline of more than 30% in any of these — flags patients at high risk of needing mechanical ventilation and should prompt elective intubation rather than waiting for a respiratory crisis.[6]
- Continuous cardiac telemetry and regular blood pressure monitoring for autonomic dysfunction; treat labile blood pressure and arrhythmia conservatively and favour short-acting agents given the unpredictable, sometimes exaggerated autonomic response in GBS.[2]
- Venous thromboembolism prophylaxis (mechanical plus pharmacologic — see Drug Tables) for every non-ambulatory patient, continued until independent ambulation resumes; deep vein thrombosis is a recognized complication of the prolonged immobility in GBS requiring standard-practice preventive measures.[2]
- Proactive nutrition support (enteral if bulbar weakness or intubation limits safe oral intake) alongside bowel and bladder monitoring for autonomic involvement.[2]
- Arrange physical, occupational, and respiratory therapy early and proactively rather than only once weaning begins — recovery is genuinely protracted for many patients.
- Encourage mobilization as early as safely possible alongside pharmacologic pain management — non-pharmacologic measures alone are not sufficient for the neuropathic pain that affects at least a third of patients at 1 year.[2]
- Screen for and address the psychological impact of a prolonged ICU stay, mechanical ventilation, and an unpredictable recovery trajectory — easy to overlook once the acute paralysis has resolved.
Special Populations
Pregnancy
GBS in pregnancy is treated the same as in a non-pregnant patient — IVIG or plasma exchange remain the disease-modifying options of choice. Involve obstetrics or maternal-fetal medicine early for shared monitoring, particularly around the airway/respiratory-monitoring plan and delivery timing.
Breastfeeding
IVIG and plasma exchange are both compatible with breastfeeding. Gabapentin and pregabalin are generally considered compatible; confirm specifics against each drug's own Drug Database entry before use.
Pediatrics
GBS in children generally follows a similar clinical course to adults, though it is often somewhat milder. Both IVIG and plasma exchange are reasonable treatment options for children with severe GBS, based on evidence extrapolated from adult trials.[3]
Older adults
Age is itself a risk factor — the average GBS rate rises by about 20% for every decade of age.[1] Older adults are more likely to have a slower, less complete recovery; maintain a lower threshold for proactive respiratory and cardiac monitoring in this group, and dose-adjust gabapentin, pregabalin, and the LMWHs for age-related renal decline.
Renal impairment
Use IVIG cautiously in renal impairment — it carries a genuine risk of IVIG-associated acute kidney injury, particularly with sucrose-stabilized formulations and in patients with pre-existing renal impairment, diabetes, or volume depletion; favour a non-sucrose formulation where available, ensure adequate hydration, and infuse at the slowest rate consistent with the product monograph. Plasma exchange avoids this specific risk and may be preferred in significant renal impairment. Adjust enoxaparin and dalteparin doses for reduced renal function; unfractionated heparin (no renal clearance dependence) is a reasonable VTE-prophylaxis alternative in severe impairment. Adjust gabapentin and pregabalin doses for reduced renal function.
Hepatic impairment
No specific IVIG or plasma exchange dose adjustment is required for hepatic impairment. Use carbamazepine cautiously given its hepatotoxicity risk, and reduce the total daily acetaminophen dose in significant hepatic impairment.
Miller Fisher syndrome and other variants
Miller Fisher syndrome — the triad of ophthalmoplegia, areflexia, and ataxia — accounts for roughly 5-25% of the GBS spectrum and tends to follow a relatively mild course, with many patients recovering without disease-modifying treatment; however, a subgroup goes on to develop limb weakness indistinguishable from classic GBS, so the same monitoring principles apply until the course is clear.[2]
IgA-deficient patients
Screen for known IgA deficiency before IVIG where feasible — the anaphylaxis risk described in the Drug Tables is specific to this population; plasma exchange is a reasonable alternative if IgA deficiency is known or strongly suspected.
Monitoring & Follow-Up
Continue serial VC/MIP/MEP monitoring and cardiac telemetry through the period of disease progression and the early plateau, not only during the initial admission.[6]
- Track the expected trajectory: clinical nadir typically occurs at 2-4 weeks, after which recovery begins; about 83% of patients can walk independently by 6 months, though persistent leg weakness, pain, and fatigue are common even after that point.[1]
- Up to two-thirds of GBS deaths occur during the recovery phase, from cardiovascular or respiratory dysfunction, particularly in patients recently discharged from ICU-level care — do not relax monitoring intensity simply because the patient has left the ICU.[2]
- Watch specifically in the weeks after apparent stabilization or initial improvement for a treatment-related fluctuation — new worsening after an initial response — which is a recognized pattern distinct from a chronic inflammatory demyelinating polyneuropathy misdiagnosis (see Treatment Failure/Next Step).[2]
- Arrange or confirm ongoing physical, occupational, and respiratory therapy at every follow-up, and reassess neuropathic pain control (see Pharmacologic Treatment Options) rather than assuming it resolves on its own.
- Complete medication reconciliation, including VTE-prophylaxis duration (stop once ambulation is independent) and any neuropathic pain agent taper plan.
Common Errors to Avoid
- Waiting for CSF or electrodiagnostic confirmation before admitting for monitoring or before starting disease-modifying therapy in a clinically convincing, progressing presentation.
- Using corticosteroids for GBS, alone or added to IVIG — Level A evidence shows no benefit, unlike in many other autoimmune neurologic conditions.[3][4]
- Combining or sequencing IVIG and plasma exchange in the hope of an additive effect — trial evidence shows no benefit over either alone.[3]
- Reassuring a patient with early, mild ascending weakness and discharging home without arranging monitoring — the course is genuinely unpredictable, and respiratory/autonomic decline can develop over hours.
- Waiting for overt respiratory distress rather than intubating electively once the 20/30/40 threshold is crossed.[6]
- Assuming CSF pleocytosis is consistent with GBS — it is a red flag for an infectious mimic instead.[1]
- Confusing GBS's ascending pattern with botulism's descending, cranial-nerve-first pattern, or missing the sensory involvement and CSF changes that point toward GBS rather than botulism.
- Discouraging routine immunization broadly because of the rare, product-specific vaccine-associated GBS signal — the appropriate response is proportionate awareness and prompt reporting, not blanket vaccine avoidance.[1][5]
- Under-treating neuropathic pain, or reaching for carbamazepine first, when gabapentin has stronger trial evidence and less sedation in this specific population.[8]
- Stopping VTE prophylaxis prematurely, or continuing it well past the point of independent ambulation without reassessing the ongoing indication.
- Attributing new, delayed deterioration to a GBS relapse without reconsidering CIDP.[2]
Clinical Decision Algorithm
Drug Tables
How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.
Disease-Modifying Immunotherapy
Equally effective (Level A) — choose based on availability, contraindications, and local expertise; do not combine or give sequentially.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Immunoglobulin (Human) — IVIG | Adults: 0.4 g/kg IV once daily for 5 consecutive days (total 2 g/kg) | Headache, aseptic meningitis, renal impairment (especially sucrose-containing formulations), thromboembolism, anaphylaxis in IgA-deficient patients | May reduce the efficacy of live vaccines given within about 3 months of infusion | Screen for IgA deficiency where feasible; favour a non-sucrose formulation and slower infusion rate in renal impairment. |
| Plasma exchange (plasmapheresis) | Adults: Five exchanges totaling about 200-250 mL plasma/kg, via a large-bore central catheter, over roughly 1-2 weeks | Hypotension, catheter-related infection or thrombosis, citrate-related hypocalcemia, coagulopathy | Removes recently administered IV drugs and some coagulation factors — coordinate timing of other IV medications with the apheresis team | Requires specialized apheresis resources and dedicated vascular access; a reasonable alternative to IVIG, particularly in IgA deficiency or significant renal impairment. |
Not Recommended — Corticosteroids
Level A evidence against benefit in GBS, at any severity, alone or added to IVIG — do not use, despite corticosteroids being foundational therapy in many other autoimmune neurologic conditions.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Methylprednisolone sodium succinate | Not recommended: No effective dose or regimen has been established for GBS | Hyperglycemia, mood/psychiatric effects, GI bleeding, immunosuppression (relevant only if inappropriately used) | Additive hyperglycemia with other agents affecting glucose control | A 233-patient randomized trial adding IV methylprednisolone 500 mg daily for 5 days to IVIG showed no significant benefit over IVIG alone. |
Neuropathic and Nociceptive Pain Management
Neuropathic pain affects at least a third of patients at 1 year and is frequently under-treated — assess and manage it as actively as the disease-modifying therapy itself.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Gabapentin | Adults: 300 mg PO three times daily, titrated to effect and renal function | Sedation, dizziness | Additive CNS depression with other sedating agents; reduced absorption with antacids | First-line — superior to carbamazepine for pain-score reduction with less sedation in a randomized ICU trial. |
| Pregabalin | Adults: 75 mg PO twice daily, titrated as tolerated | Sedation, dizziness, peripheral edema | Additive CNS depression with other sedating agents | A reasonable substitute where gabapentin is not tolerated or available. |
| Carbamazepine | Adults: 100 mg PO three times daily | Sedation, hyponatremia, hepatotoxicity, rare severe cutaneous reactions (higher risk with certain HLA genotypes) | Potent CYP3A4 inducer — reduces levels of many co-administered drugs | Second-line — inferior to gabapentin for pain control in a head-to-head ICU trial. |
| Acetaminophen | Adults: 975-1000 mg PO/IV every 6 hours, maximum 4 g/day | Hepatotoxicity with overdose or significant hepatic impairment | None significant at standard doses | First step or adjunct for mild-moderate nociceptive pain alongside a neuropathic agent. |
VTE Prophylaxis (Non-Ambulatory Patients)
Continue mechanical plus pharmacologic prophylaxis until the patient regains independent ambulation.
| Drug | Dosage | Adverse effects | Drug interactions | Comments |
|---|---|---|---|---|
| Enoxaparin | Adults: 40 mg SC once daily | Bleeding, injection-site bruising, rare heparin-induced thrombocytopenia (HIT) | Additive bleeding risk with antiplatelet agents or anticoagulants | Preferred LMWH; renally adjust the dose. |
| Dalteparin | Adults: 5,000 units SC once daily | Bleeding, rare HIT | Additive bleeding risk with antiplatelet agents or anticoagulants | An alternative LMWH where enoxaparin is unavailable or not preferred locally. |
| Heparin (unfractionated) | Adults: 5,000 units SC every 8-12 hours | Bleeding, HIT, osteoporosis with prolonged use | Additive bleeding risk with antiplatelet agents or anticoagulants | Preferred over an LMWH in severe renal impairment, given no renal clearance dependence. |
References
- Guillain–Barré syndrome — CMAJ, Canadian Medical Association Journal (Mirian A, Nicolle MW, Budhram A). CMAJ 2021;193(11):E378
- Diagnosis and management of Guillain–Barré syndrome in ten steps — Nature Reviews Neurology (Leonhard SE, Mandarakas MR, Gondim FAA, et al.). Nat Rev Neurol 2019;15(11):671-683
- Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology — Neurology, American Academy of Neurology (Hughes RA, Wijdicks EF, Barohn R, et al.). Neurology 2003;61(6):736-740
- Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial — The Lancet (van Koningsveld R, Schmidt J, Van Doorn PA, et al.). Lancet 2004;363(9404):192-196
- COVID-19 vaccine safety: Weekly report on side effects following immunization (archived October 22, 2021) — Public Health Agency of Canada / Health Canada. Government of Canada, health-infobase.canada.ca, October 22, 2021
- Anticipating mechanical ventilation in Guillain-Barré syndrome — Archives of Neurology (Lawn ND, Fletcher DD, Henderson RD, Wolter TD, Wijdicks EF). Arch Neurol 2001;58(6):893-898
- Prediction of respiratory insufficiency in Guillain-Barré syndrome — Annals of Neurology (Walgaard C, Lingsma HF, Ruts L, et al.). Ann Neurol 2010;67(6):781-787
- The comparative evaluation of gabapentin and carbamazepine for pain management in Guillain-Barré syndrome patients in the intensive care unit — Anesthesia & Analgesia (Pandey CK, Raza M, Tripathi M, Navkar DV, Kumar A, Singh UK). Anesth Analg 2005;101(1):220-225
Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.